masthead-image1

Transformative Diagnostics

Transitioning complex immunoassay blood tests directly to the point-of-care More »

 

Rapidly identifying disease-specific antibodies More »

diagnostic-machine
masthead-image2

Next-Generation Therapies & Vaccines

Addressing novel biological mechanisms for Parkinson’s disease, respiratory diseases, supportive care, and protein up-regulation More »

masthead-image3

Worldwide Production & Distribution

Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »

masthead-image4

Strategic Investments

Identifying early-stage companies with potential to increase value for shareholders More »

Chairman’s Message

read more »

OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.

News & Events

more news »

OPKO Surpasses 50% Enrollment in First Phase 3 Trial of RayaldyTM (CTAP101 Capsules) more »

OPKO Announces First Quarter 2013 Operating and Financial Highlights more »

OPKO Health to Acquire PROLOR Biotech more »

Investors

read more »

OPKO Health is an opportunistic research and development company that targets large, high-growth markets.

 

2013 OPKO JP Morgan Healthcare Conference Presentation

 

2013 Cytochroma Corporate Presentation